Tekmira Pharmaceuticals Corporation achieves $1.5 million development milestone from Monsanto
Vancouver, British Columbia , Canada
October 2, 2104
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has achieved a development milestone supporting a $1.5 million payment from Monsanto, following completion of specified program objectives. This work is part of the research program under the Option Agreement Tekmira signed with the agriculture company, which the Company announced on January 13, 2014. The Option Agreement relates to Tekmira's proprietary delivery technology and intellectual property for use in agricultural applications. The potential value of the transaction could reach up to $86.2 million, following the successful completion of all program milestones.
More news from: . Tekmira Pharmaceuticals Corporation . Monsanto Company
Website: http://www.tekmirapharm.com/Home.asp Published: October 4, 2014 |
The news item on this page is copyright by the organization where it originated Fair use notice |